De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer.
De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer.
复制标题
DOI：
10.1186/s41199-016-0016-7
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Husain, Zain A
中科院分区：
文献类型：
--
作者：
An, Yi;Holsinger, F Christopher;Husain, Zain A
目前口咽鳞状细胞癌初次手术治疗的辅助治疗指南是基于早于人类乳头瘤病毒(HPV)时代的研究。人乳头瘤病毒相关性口咽癌(HPV-OPC)与HPV非相关癌相比预后更好，并因其独特的病因、表现和行为而日益被认为是一种独特的疾病实体。目前，人们对HPV-OPC患者的辅助治疗去强化治疗非常感兴趣，以便在保持良好临床结果的同时减少与治疗相关的毒性。在这里，我们回顾了正在进行的针对HPV-OPC患者的辅助治疗去强化的前瞻性试验的证据和基本原理。
Current adjuvant treatment guidelines for oropharyngeal squamous cell carcinoma treated with primary surgery are based on studies that predate the human papillomavirus (HPV) era. HPV-associated oropharynx carcinoma (HPV-OPC) has a much more favorable prognosis compared to HPV-unassociated cancer and is increasingly considered to be a distinct disease entity due to its unique etiology, presentation, and behavior. Currently, there is significant interest in adjuvant treatment de-intensification of HPV-OPC patients in order to reduce treatment-related toxicity while maintaining excellent clinical outcomes. Here, we review the evidence and rationale underlying the ongoing prospective trials of adjuvant treatment de-intensification for HPV-OPC patients.